VRTX

Vertex Pharmaceuticals
VRTX

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$116.96B
EV
$107.25B
Shares Outstanding
257.84M
Beta
0.42

Wall Street View

Analyst Rating
OUTPERFORM
Analyst Target Price
$500.12
P/E 2025E
25.31x
P/Revenue 2025E
9.82x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Vertex Pharmaceuticals Incorporated

gainify
VRTX

Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/...

Sector

Healthcare

Industry

Biotechnology

CEO

Kewalramani, Reshma

Employees

6,100

IPO Date

1991-07-24

Headquarters

50 Northern Avenue, Boston, Massachusetts, 02210, United States

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on Trustpilot
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.